Michael Krainer
Michael Krainer
Professor für Onkologie
Verified email at prof-krainer.at
TitleCited byYear
Increased survival with enzalutamide in prostate cancer after chemotherapy
HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R de Wit, ...
New England Journal of Medicine 367 (13), 1187-1197, 2012
31222012
Enzalutamide in metastatic prostate cancer before chemotherapy
TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
New England Journal of Medicine 371 (5), 424-433, 2014
17162014
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
K Fizazi, M Carducci, M Smith, R Damião, J Brown, L Karsh, P Milecki, ...
The Lancet 377 (9768), 813-822, 2011
16882011
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer …
DH Henry, L Costa, F Goldwasser, V Hirsh, V Hungria, J Prausova, ...
J Clin Oncol 29 (9), 1125-1132, 2011
10062011
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a …
ED Kwon, CG Drake, HI Scher, K Fizazi, A Bossi, AJM Van den Eertwegh, ...
The lancet oncology 15 (7), 700-712, 2014
7842014
Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome
KE Nichols, DP Harkin, S Levitz, M Krainer, KA Kolquist, C Genovese, ...
Proceedings of the National Academy of Sciences 95 (23), 13765-13770, 1998
4981998
Germ-Line BRCA1 Mutations in Jewish and Non-Jewish Women with Early-Onset Breast Cancer
MG FitzGerald, DJ MacDonald, M Krainer, I Hoover, E O'Neil, H Unsal, ...
New England Journal of Medicine 334 (3), 143-149, 1996
4641996
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families
P Tonin, B Weber, K Offit, F Couch, TR Rebbeck, S Neuhausen, ...
Nature medicine 2 (11), 1179, 1996
3531996
Differential Contributions of BRCA1 and BRCA2 to Early-Onset Breast Cancer
M Krainer, S Silva-Arrieta, MG FitzGerald, A Shimada, C Ishioka, ...
New England journal of medicine 336 (20), 1416-1422, 1997
2871997
Third consensus on medical treatment of metastatic breast cancer
S Beslija, J Bonneterre, HJ Burstein, V Cocquyt, M Gnant, V Heinemann, ...
Annals of oncology 20 (11), 1771-1785, 2009
1942009
Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer
WJ Köstler, B Schwab, CF Singer, R Neumann, E Rücklinger, ...
Clinical Cancer Research 10 (5), 1618-1624, 2004
1802004
Interleukin-6 is a prognostic factor in multiple myeloma [letter][see comments]
H Ludwig, DM Nachbaur, E Fritz, M Krainer, H Huber
Blood 77 (12), 2794-2795, 1991
1661991
Contribution of epigenetic silencing of tumor necrosis factor–related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer
P Horak, D Pils, G Haller, I Pribill, M Roessler, S Tomek, R Horvat, ...
Molecular cancer research 3 (6), 335-343, 2005
1562005
Second consensus on medical treatment of metastatic breast cancer
S Beslija, J Bonneterre, H Burstein, V Cocquyt, M Gnant, P Goodwin, ...
Annals of Oncology 18 (2), 215-225, 2006
1312006
Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1.
M Smith, J De Bono, C Sternberg, S Le Moulec, S Oudard, U De Giorgi, ...
1202016
Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors
H Ludwig, E Fritz, C Leitgeb, M Krainer, I Kührer, P Sagaster, H Umek
Annals of oncology 4 (2), 161-167, 1993
1151993
Doubling epirubicin dose intensity (100 mg/m2versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III …
G Brufman, E Colajori, N Ghilezan, M Lassus, M Martoni, ...
Annals of oncology 8 (2), 155-162, 1997
1071997
Five genes from chromosomal band 8p22 are significantly down‐regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival
D Pils, P Horak, A Gleiss, C Sax, G Fabjani, VJ Moebus, C Zielinski, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2005
1042005
Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients
E Obermayr, F Sanchez-Cabo, MKM Tea, CF Singer, M Krainer, ...
BMC cancer 10 (1), 666, 2010
1002010
In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway
D Pils, A Pinter, J Reibenwein, A Alfanz, P Horak, BC Schmid, L Hefler, ...
British journal of cancer 96 (3), 485, 2007
952007
The system can't perform the operation now. Try again later.
Articles 1–20